0000899243-19-002525.txt : 20190204
0000899243-19-002525.hdr.sgml : 20190204
20190204190956
ACCESSION NUMBER: 0000899243-19-002525
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190131
FILED AS OF DATE: 20190204
DATE AS OF CHANGE: 20190204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Thomas B
CENTRAL INDEX KEY: 0001748462
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 19565803
MAIL ADDRESS:
STREET 1: BIODELIVERY SCIENCES INTERNATIONAL, INC.
STREET 2: 4131 PARKLAKE AVE SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-31
0
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001748462
Smith Thomas B
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVE. SUITE 225
RALEIGH
NC
27612
0
1
0
0
Chief Medical Officer
Restricted Stock Units
0.00
2019-01-31
4
A
0
23000
0.00
A
2022-01-31
Common Stock
23000
23000
D
Stock Options (right to buy)
3.90
2019-01-31
4
A
0
130000
0.00
A
2029-01-31
Common Stock
130000
130000
D
The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 31, 2019, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 31, 2020; (ii) January 31, 2021; and (iii) January 31, 2022.
Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A.
The exercise price of the stock options issued to the Reporting Person is the volume-weighted average price of the Company's common stock for the 30-day period ending on January 30, 2019.
The stock options were issued to the Reporting Person on January 31, 2019, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 31, 2020; (ii) January 31, 2021; and (iii) January 31, 2022.
/s/ Thomas Smith, MD.
2019-02-04